| Ytd | -12.45% | |
| 1y | 28.85% |
| Open | 6.44 | Prev Close | 6.38 | Low | 6.40 | High | 6.83 | Mkt Cap | 213.60M |
| Vol | 718.39K | Avg Vol | 292.14K | EPS | -1.05 | P/E | -6.08 | Forward P/E | N/A |
| Beta | 1.05 | Short Ratio | 27.74 | Inst. Own | 12.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 6.62 | 200-d Avg | 6.99 | 1yr Est | 0.00 |
EPRX News
VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupra
Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VANCOUVER, British Columbia, May 28, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax
US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $39
Gainers: PHGE +97.3%, ARTL +74.8%, QTEX +52.4%, MNTX +34.4%, HLIT +28.3%, WOK +25%, CPSH +24.7%, COD
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Compl
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue dam
EREFS is a standardized visual scoring system that gastroenterologists use when performing an endosc
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Euprax
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupr
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinic
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85,
Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) in th
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupra
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Euprax
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosin
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in Eu
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-1